Tyche Wealth Partners’s Coherus Oncology CHRS Stock Holding History

Tyche Wealth Partners’s Portfolio CHRS Stock Details CHRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$174K	Sell	144,202 -57,000	-28%	-$78K	0.02%	338
2026 Q2	$282K	Sell	201,202 -39,666	-16%	-$64.8K	0.04%	273
2026 Q1	$407K	Buy	240,868 +20,000	+9%	+$35.5K	0.06%	229
2025 Q4	$314K	Buy	220,868 +25,000	+13%	+$36.4K	0.05%	257
2025 Q3	$321K	Sell	195,868 -14,000	-7%	-$15.6K	0.06%	223
2025 Q2	$153K	Sell	209,868 -55,898	-21%	-$48.3K	0.03%	286
2025 Q1	$214K	Sell	265,766 -1,000	-0.4%	-$1.15K	0.05%	263
2024 Q4	$368K	Buy	266,766 +50,864	+24%	+$57.1K	0.08%	184
2024 Q3	$225K	Hold	215,902	–	–	0.05%	254
2024 Q2	$374K	Hold	215,902	–	–	0.09%	161
2024 Q1	$516K	Hold	215,902	–	–	0.13%	133
2023 Q4	$719K	Buy	+215,902	New	+$578K	0.17%	112

Other funds holding CHRS

TGY2IT

Timothy G. Youngquist 2020 Irrevocable Trust Fort Myers, Florida $530M AUM 95.29% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

C WorldWide Group Copenhagen, Denmark $3.96B AUM 10.41% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return

Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $85.7B AUM 51.02% 1-Year Est. Return

Citigroup New York $308B AUM 40.94% 1-Year Est. Return

RhumbLine Advisers Boston, Massachusetts $134B AUM 35.21% 1-Year Est. Return

Tyche Wealth Partners's CHRS Position: Q3 2026 in Review

Tyche Wealth Partners reduced its Coherus Oncology (CHRS) stake by 28% in Q3 2026, selling an estimated $78K and leaving 144,202 shares worth $174K. The position accounts for 0.02% of the portfolio, ranked #338.

Tyche Wealth Partners first reported a position in CHRS in Q4 2023 and has held it in 12 quarters since. The position peaked at $719K in Q4 2023. 59 funds tracked by Wall St. Rank hold CHRS as of Q3 2026.

Tyche Wealth Partners held 144,202 shares of Coherus Oncology worth $174K as of Q3 2026.
Tyche Wealth Partners sold 57,000 Coherus Oncology shares in Q3 2026, an estimated $78K.
Coherus Oncology made up 0.02% of Tyche Wealth Partners's portfolio in Q3 2026, its #338 holding.
Tyche Wealth Partners first reported a position in Coherus Oncology in Q4 2023 and has held it in 12 quarters since.
Tyche Wealth Partners's Coherus Oncology position peaked at $719K in Q4 2023.
59 funds tracked by Wall St. Rank held Coherus Oncology as of Q3 2026.

Based on Tyche Wealth Partners's 13F filing for Q3 2026, filed 10 Nov 2026.